Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme

Journal of Neuro-Oncology

Volumn 98, Issue 1, 2010, Pages 93-99

  Peereboom, David M ^a   Shepard, Dale R ^a   Ahluwalia, Manmeet S ^a   Brewer, Cathy J ^a   Agarwal, Neeraj ^a   Stevens, Glen H J ^a   Suh, John H ^a   Toms, Steven A ^b   Vogelbaum, Michael A ^a   Weil, Robert J ^a   Elson, Paul ^a   Barnett, Gene H ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b GEISINGER HEALTH SYSTEM   (United States)

Author keywords

Chemotherapy; Efficacy; EGFR inhibitor; Erlotinib; Glioblastoma multiforme; Newly diagnosed; Phase II; Temozolomide

Indexed keywords

ANTICONVULSIVE AGENT; ANTIINFECTIVE AGENT; CORTICOSTEROID DERIVATIVE; ERLOTINIB; ETIRACETAM; HEMOPOIETIC GROWTH FACTOR; MINOCYCLINE; PENTAMIDINE; RETINOID; TEMOZOLOMIDE; TETRACYCLINE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; GLIOBLASTOMA; HUMAN; LYMPHOCYTOPENIA; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PATIENT COMPLIANCE; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; PROGRESSION FREE SURVIVAL; RADIATION DOSE FRACTIONATION; SEIZURE; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; DACARBAZINE; DISEASE-FREE SURVIVAL; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GLIOBLASTOMA; HUMANS; KARNOFSKY PERFORMANCE STATUS; MAGNETIC RESONANCE IMAGING; MALE; METHYLATION; MIDDLE AGED; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RADIOTHERAPY; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 77953617053     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-009-0067-2     Document Type: Article

References (42)

1. JW Henson 2006 Treatment of glioblastoma multiforme: a new standard Arch Neurol 63 337 341 10.1001/archneur.63.3.337 16533960
2. R Stupp WP Mason MJ van den Bent, et al. 2005 Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987 996 10.1056/NEJMoa043330 1:CAS:528:DC%2BD2MXit1Wksbk%3D 15758009 (Pubitemid 40349501)
3. LA Stewart 2002 Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials Lancet 359 1011 1018 10.1016/S0140-6736(02)08091-1 1:CAS:528: DC%2BD38XisV2htro%3D 11937180 (Pubitemid 34286538)
4. TA Libermann HR Nusbaum N Razon, et al. 1985 Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin Nature 313 144 147 10.1038/313144a0 1:CAS:528:DyaL2MXhtVOgsbg%3D 2981413 (Pubitemid 15192341)
5. J Schlegel A Merdes G Stumm, et al. 1994 Amplification of the epidermal-growth-factor-receptor gene correlates with different growth behaviour in human glioblastoma Int J Cancer 56 72 77 1:STN:280:DyaK2c%2Fos1Wltw%3D%3D 8262681
6. P Tang PA Steck WK Yung 1997 The autocrine loop of TGF-alpha/EGFR and brain tumors J Neurooncol 35 303 314 10.1023/A:1005824802617 1:STN:280:DyaK1c7gtlajsw%3D%3D 9440027 (Pubitemid 27511133)
7. ME Halatsch E Gehrke FA Borhani, et al. 2003 EGFR but not PDGFR-beta expression correlates to the antiproliferative effect of growth factor withdrawal in glioblastoma multiforme cell lines Anticancer Res 23 2315 2320 1:CAS:528:DC%2BD3sXmsFyrt7o%3D 12894509
8. M Lund-Johansen R Bjerkvig PA Humphrey SH Bigner DD Bigner OD Laerum 1990 Effect of epidermal growth factor on glioma cell growth, migration, and invasion in vitro Cancer Res 50 6039 6044 1:CAS:528:DyaK3cXlvVGgtbs%3D 2393868
9. N Shinojima K Tada S Shiraishi, et al. 2003 Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme Cancer Res 63 6962 6970 1:CAS:528:DC%2BD3sXosVGnsLg%3D 14583498
10. FG Barker II ML Simmons SM Chang, et al. 2001 EGFR overexpression and radiation response in glioblastoma multiforme Int J Radiat Oncol Biol Phys 51 410 418 1:CAS:528:DC%2BD3MXmvVyltb0%3D 11567815
11. A Chakravarti A Chakladar MA Delaney DE Latham JS Loeffler 2002 The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner Cancer Res 62 4307 4315 1:CAS:528: DC%2BD38XlvFeltbY%3D 12154034
12. Moore MJ, Goldstein D, Hamm J et al. (2005) Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). 2005 Gastrointestinal Cancers Symposium. Proc Am Soc Clin Oncol 2005:121. Abstract 77. Available at http://www.asco.org
13. FA Shepherd J Rodrigues Pereira T Ciuleanu, et al. 2005 Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 123 132 10.1056/NEJMoa050753 1:CAS:528:DC%2BD2MXmtFaksbo%3D 16014882 (Pubitemid 41058344)
14. ME Halatsch EE Gehrke VI Vougioukas, et al. 2004 Inverse correlation of epidermal growth factor receptor messenger RNA induction and suppression of anchorage-independent growth by OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in glioblastoma multiforme cell lines J Neurosurg 100 523 533 10.3171/jns.2004.100.3.0523 1:CAS:528:DC%2BD2cXitlyms70%3D 15035290
15. Iwata KK, Provoncha K, Gibson N (2002) Inhibition of mutant EGFRvIII transformed cells by tyrosine kinase inhibitor OSI-774 (Tarceva). Proc Am Soc Clin Oncol 21:Abstract 79
16. MD Prados KR Lamborn S Chang, et al. 2006 Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma Neuro Oncol 8 67 78 10.1215/S1522851705000451 1:CAS:528:DC%2BD28Xps1amtw%3D%3D 16443950 (Pubitemid 43154453)
17. Vogelbaum MA, Peereboom D, Stevens G, Barnett GH, Brewer C (2004) Response rate to single agent therapy with the EGFR tyrosine kinase inhibitor erlotinib in recurrent glioblastoma multiforme: results of a phase II study. In: Proceedings of the ninth meeting of the society for neuro-oncology 384. Abstract TA-59
18. S Krishnan PD Brown KV Ballman, et al. 2006 Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177 Int J Radiat Oncol Biol Phys 65 1192 1199 1:CAS:528:DC%2BD28Xmt1Gkurk%3D 16626884 Epub 2006 Apr 19
19. R Perez-Soler A Chachoua LA Hammond, et al. 2004 Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer J Clin Oncol 22 3238 3247 10.1200/JCO.2004.11.057 1:CAS:528: DC%2BD2cXpsVGrsLg%3D 15310767 (Pubitemid 41103678)
20. SA Grossman A O'Neill M Grunnet M Mehta JL Pearlman H Wagner, et al. 2003 Phase III study comparing three cycles of infusional carmustine, cisplatin followed by radiation therapy with radiation therapy, concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394 J Clin Oncol 21 8 1485 1491 10.1200/JCO.2003.10.035 1:CAS:528:DC%2BD2cXptlCksL4%3D 12697871 (Pubitemid 46594100)
21. M Barrie C Couprie H Dufour D Figarella-Branger X Muracciole K Hoang-Xuan, et al. 2005 Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme Ann Oncol 16 7 1177 1184 10.1093/annonc/mdi225 1:STN:280:DC%2BD2Mzmslyktw%3D%3D 15857844 (Pubitemid 41418322)
22. VA Levin S Phuphanich WK Yung PA Forsyth RD Maestro JR Perry, et al. 2006 Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation J Neurooncol 78 3 295 302 10.1007/s11060-005-9098-5 1:CAS:528:DC%2BD28Xpt1yltL4%3D 16636750 (Pubitemid 44018824)
23. JF Parkinson HR Wheeler A Clarkson, et al. 2008 Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma J Neurooncol 87 71 78 10.1007/s11060-007-9486-0 1:CAS:528:DC%2BD1cXivFygtro%3D 18004504
24. WJ Curran Jr CB Scott J Horton JS Nelson AS Weinstein AJ Fischbach, et al. 1993 Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials J Natl Cancer Inst 85 9 704 710 10.1093/jnci/85.9.704 8478956
25. MC Chamberlain MJ Glantz L Chalmers A Van Horn AE Sloan 2007 Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma J Neurooncol 82 81 83 10.1007/s11060-006-9241-y 16944309
26. E Franceschi G Cavallo S Lonardi, et al. 2007 Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO) Br J Cancer 96 1047 1051 10.1038/sj.bjc.6603669 1:CAS:528:DC%2BD2sXjsleksLw%3D 17353924 (Pubitemid 46608313)
27. IK Mellinghoff MY Wang I Vivanco, et al. 2005 Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors N Engl J Med 353 2012 2024 10.1056/NEJMoa051918 1:CAS:528:DC%2BD2MXht1SrtrrE 16282176 (Pubitemid 41609094)
28. JN Rich DA Reardon T Peery, et al. 2004 Phase II trial of gefitinib in recurrent glioblastoma J Clin Oncol 22 133 142 10.1200/JCO.2004.08.110 1:CAS:528:DC%2BD2cXpsVKhsr8%3D 14638850 Epub 2003 Nov 24 (Pubitemid 41095125)
29. B Stea R Falsey K Kislin, et al. 2003 Time and dose-dependent radiosensitization of the glioblastoma multiforme U251 cells by the EGF receptor tyrosine kinase inhibitor ZD1839 ('Iressa') Cancer Lett 202 43 51 10.1016/j.canlet.2003.07.006 1:CAS:528:DC%2BD3sXpt1elurk%3D 14643025 (Pubitemid 37464897)
30. G Giaccone RS Herbst C Manegold, et al. 2004 Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1 J Clin Oncol 22 777 784 10.1200/JCO.2004.08.001 1:CAS:528:DC%2BD2cXpsVKjur4%3D 14990632 (Pubitemid 41103588)
31. RS Herbst G Giaccone JH Schiller, et al. 2004 Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2 J Clin Oncol 22 785 794 10.1200/JCO.2004.07.215 1:CAS:528:DC%2BD2cXpsVKjur0%3D 14990633 (Pubitemid 41103589)
32. RS Herbst D Prager R Hermann, et al. 2005 TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer J Clin Oncol 23 5892 5899 10.1200/JCO.2005.02.840 1:CAS:528:DC%2BD2MXhtVKgtbzN 16043829 Epub 2005 Jul 25
33. JM Stommel AC Kimmelman H Ying, et al. 2007 Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies Science 318 287 290 10.1126/science.1142946 1:CAS:528:DC%2BD2sXhtFCjt7vP 17872411 (Pubitemid 47574858)
34. DB Solit Y She J Lobo, et al. 2005 Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel Clin Cancer Res 11 1983 1989 10.1158/1078-0432.CCR-04-1347 1:CAS:528: DC%2BD2MXitVKrsbo%3D 15756024 (Pubitemid 40471864)
35. T Li YH Ling ID Goldman R Perez-Soler 2007 Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells Clin Cancer Res 13 3413 3422 10.1158/1078-0432.CCR-06-2923 1:CAS:528: DC%2BD2sXmtVais74%3D 17545550 (Pubitemid 46944930)
36. B Piperdi YH Ling R Perez-Soler 2007 Schedule-dependent interaction between the proteosome inhibitor bortezomib and the EGFR-TK inhibitor erlotinib in human non-small cell lung cancer cell lines J Thorac Oncol 2 715 721 10.1097/JTO.0b013e3180f60bb3 17762337 (Pubitemid 47357523)
37. Y Hirose MS Berger RO Pieper 2001 p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells Cancer Res 61 1957 1963 1:CAS:528:DC%2BD3MXit1Ogsrk%3D 11280752
38. ME Hegi AC Diserens S Godard, et al. 2004 Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide Clin Cancer Res 10 1871 1874 10.1158/1078-0432.CCR-03-0384 1:CAS:528:DC%2BD2cXisVGltbY%3D 15041700 (Pubitemid 38375541)
39. CA Learn TL Hartzell CJ Wikstrand, et al. 2004 Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme Clin Cancer Res 10 3216 3224 10.1158/1078-0432.CCR-03-0521 1:CAS:528:DC%2BD2cXjs12lt7Y%3D 15131063 (Pubitemid 38619703)
40. JP Bach AM Kiessling A Kleinhans, et al. 2006 Pulmonary fibrosis in a patient treated with erlotinib Onkologie 29 342 343 10.1159/000093663 16874020 Epub 2006 Jul 3 (Pubitemid 44022410)
41. MD Prados SM Chang N Butowski, et al. 2009 Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma J Clin Oncol 27 579 584 10.1200/JCO.2008.18.9639 1:CAS:528:DC%2BD1MXivFyjurk%3D 19075262
42. PD Brown S Krishnan JN Sarkaria, et al. 2008 Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177 J Clin Oncol 26 5603 5609 10.1200/JCO.2008.18.0612 1:CAS:528: DC%2BD1MXmsVSrsg%3D%3D 18955445